RASSF6-TRIM16 axis promotes cell proliferation, migration and invasion in esophageal squamous cell carcinoma

Leilei Zheng; Zitong Zhao; Lulu Rong; Liyan Xue; Yongmei Song

doi:10.1016/j.jgg.2019.10.004

Volume 46 Issue 10

Oct. 2019

Turn off MathJax

Article Contents

Article Navigation > Journal of Genetics and Genomics > 2019 > 46(10): 477-488

PDF( 5183 KB)

RASSF6-TRIM16 axis promotes cell proliferation, migration and invasion in esophageal squamous cell carcinoma

doi: 10.1016/j.jgg.2019.10.004

a
State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
b
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

More Information

Corresponding author: E-mail address: xueliyan2003@126.com (Liyan Xue); E-mail address: symlh2006@163.com (Yongmei Song)
Received Date: 2019-07-22
Accepted Date: 2019-10-17
Rev Recd Date: 2019-09-21

Available Online: 2019-11-14

Publish Date: 2019-10-20

Abstract

Abstract

Ras-association (RA) domain family number 6 (RASSF6) is a member of the Ras-association domain protein family. It is epigenetically inactive and negatively regulates the malignant progression of some tumors. However, its precise role in esophageal squamous cell carcinoma (ESCC) has not been reported. In this study, we performed immunohistochemistry (IHC) assay. The results show that RASSF6 is upregulated in ESCC and that the elevated expression level of RASSF6 is associated with lymph node metastasis and poor survival of ESCC patients. Consistent with the clinical observations, the upregulation of RASSF6 greatly promotes ESCC cell proliferation, migration and invasion as well as the cell cycle transition to G1/S phasein vitro. According to models in vivo, the downregulation of RASSF6 considerably inhibits ESCC tumor growth and lung metastasis. Mechanistically, RASSF6 negatively regulates the tumor suppressor tripartite-motif-containing protein 16 (TRIM16) by promoting its ubiquitination-dependent degradation and eventually activates pathways associated with the cell cycle and epithelial-mesenchymal transition (EMT). Together, these results indicate that the RASSF6-TRIM16 axis is a key effector in ESCC progression and that RASSF6 serves as a potential target for the treatment of ESCC.
- Esophageal squamous cell cancer,
- RASSF6,
- Cell cycle,
- EMT,
- TRIM16

These authors contributed equally to this work.

FullText(HTML)

References(34)

References

[1]	Allen, N.P., Donninger, H., Vos, M.D., Eckfeld, K., Hesson, L., Gordon, L., Birrer, M.J., Latif, F., Clark, G.J., 2007. RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene 26, 6203-6211.
[2]	Arnold, M., Soerjomataram, I., Ferlay, J., Forman, D., 2015. Global incidence of oesophageal cancer by histological subtype in 2012. Gut 64, 381-387.
[3]	Bell, J.L., Malyukova, A., Kavallaris, M., Marshall, G.M., Cheung, B.B., 2013. TRIM16 inhibits neuroblastoma cell proliferation through cell cycle regulation and dynamic nuclear localization. Cell Cycle 12, 889-898.
[4]	Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394-424.
[5]	Cancer Genome Atlas Research, N., Analysis Working Group: Asan, U., Agency, B.C.C., Brigham, Women's, H., Broad, I., Brown, U., Case Western Reserve, U., Dana-Farber Cancer, I., Duke, U., Greater Poland Cancer, C., Harvard Medical, S., Institute for Systems, B., Leuven, K.U., Mayo, C., Memorial Sloan Kettering Cancer, C., National Cancer, I., Nationwide Children's, H., Stanford, U., University of, A., University of, M., University of North, C., University of, P., University of, R., University of Southern, C., University of Texas, M.D.A.C.C., University of, W., Van Andel Research, I., Vanderbilt, U., Washington, U., Genome Sequencing Center: Broad, I., Washington University in St, L., Genome Characterization Centers, B.C.C.A., Broad, I., Harvard Medical, S., Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, U., University of North, C., University of Southern California Epigenome, C., University of Texas, M.D.A.C.C., Van Andel Research, I., Genome Data Analysis Centers: Broad, I., Brown, U., Harvard Medical, S., Institute for Systems, B., Memorial Sloan Kettering Cancer, C., University of California Santa, C., University of Texas, M.D.A.C.C., Biospecimen Core Resource: International Genomics, C., Research Institute at Nationwide Children's, H., Tissue Source Sites: Analytic Biologic, S., Asan Medical, C., Asterand, B., Barretos Cancer, H., BioreclamationIvt, Botkin Municipal, C., Chonnam National University Medical, S., Christiana Care Health, S., Cureline, Duke, U., Emory, U., Erasmus, U., Indiana University School of, M., Institute of Oncology of, M., International Genomics, C., Invidumed, Israelitisches Krankenhaus, H., Keimyung University School of, M., Memorial Sloan Kettering Cancer, C., National Cancer Center, G., Ontario Tumour, B., Peter MacCallum Cancer, C., Pusan National University Medical, S., Ribeirao Preto Medical, S., St. Joseph's, H., Medical, C., St. Petersburg Academic, U., Tayside Tissue, B., University of, D., University of Kansas Medical, C., University of, M., University of North Carolina at Chapel, H., University of Pittsburgh School of, M., University of Texas, M.D.A.C.C., Disease Working Group: Duke, U., Memorial Sloan Kettering Cancer, C., National Cancer, I., University of Texas, M.D.A.C.C., Yonsei University College of, M., Data Coordination Center, C.I., Project Team: National Institutes of, H., 2017. Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169-175.
[6]	Chen E., Yang F., He H., Lei L., Liu R., Du L., Dong J., Wang M., Yang J., 2016. Decreased level of RASSF6 in sporadic colorectal cancer and its anti-tumor effects both in vitro and in vivo. Oncotarget 7, 19813-19823.
[7]	Chen, W., Zheng, R., Baade, P.D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X.Q., He, J., 2016. Cancer statistics in China, 2015. CA Cancer J. Clin. 66, 115-132.
[8]	De Craene, B., Berx, G., 2013. Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 13, 97-110.
[9]	Di Rienzo, M., Piacentini, M., Fimia, G.M., 2019. A TRIM32-AMBRA1-ULK1 complex initiates the autophagy response in atrophic muscle cells. Autophagy 15, 1674-1676.
[10]	Guo, W., Dong, Z., Guo, Y., Shen, S., Guo, X., Kuang, G., Yang, Z., 2016. Decreased expression and frequent promoter hypermethylation of RASSF2 and RASSF6 correlate with malignant progression and poor prognosis of gastric cardia adenocarcinoma. Mol. Carcinog. 55, 1655-1666.
[11]	Hao, D., Ritter, M.A., Oliver, T., Browman, G.P., 2006. Platinum-based concurrent chemoradiotherapy for tumors of the head and neck and the esophagus. Semin. Radiat. Oncol. 16, 10-19.
[12]	Harvey, K., Tapon, N., 2007. The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. Nat. Rev. Cancer 7, 182-191.
[13]	He, Z., Zhao, T.T., Jin, F., Li, J.G., Xu, Y.Y., Dong, H.T., Liu, Q., Xing, P., Zhu, G.L., Xu, H., Miao, Z.F., 2018. Downregulation of RASSF6 promotes breast cancer growth and chemoresistance through regulation of Hippo signaling. Biochem. Biophys. Res. Commun. 503, 2340-2347.
[14]	Hesson, L.B., Dunwell, T.L., Cooper, W.N., Catchpoole, D., Brini, A.T., Chiaramonte, R., Griffiths, M., Chalmers, A.D., Maher, E.R., Latif, F., 2009. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol. Cancer 8, 42.
[15]	Huo, X., Li, S., Shi, T., Suo, A., Ruan, Z., Yao, Y., 2015. Tripartite motif 16 inhibits epithelial-mesenchymal transition and metastasis by down-regulating sonic hedgehog pathway in non-small cell lung cancer cells. Biochem. Biophys. Res. Commun. 460, 1021-1028.
[16]	Ikeda, M., Hirabayashi, S., Fujiwara, N., Mori, H., Kawata, A., Iida, J., Bao, Y., Sato, Y., Iida, T., Sugimura, H., Hata, Y., 2007. Ras-association domain family protein 6 induces apoptosis via both caspase-dependent and caspase-independent pathways. Exp. Cell Res. 313, 1484-1495.
[17]	Li, L., Dong, L., Qu, X., Jin, S., Lv, X., Tan, G., 2016. Tripartite motif 16 inhibits hepatocellular carcinoma cell migration and invasion. Int. J. Oncol. 48, 1639-1649.
[18]	Liang, Y.Y., Chen, M.Y., Hua, Y.J., Chen, S., Zheng, L.S., Cao, X., Peng, L.X., Xie, P., Huang, B.J., Sun, R., Wang, L., Xiang, Y.Q., Guo, X., Qian, C.N., 2014. Downregulation of Ras association domain family member 6 (RASSF6) underlies the treatment resistance of highly metastatic nasopharyngeal carcinoma cells. PLoS One 9, e100843.
[19]	Luo, L.N., He, L.J., Gao, X.Y., Huang, X.X., Shan, H.B., Luo, G.Y., Li, Y., Lin, S.Y., Wang, G.B., Zhang, R., Xu, G.L., Li, J.J., 2016. Evaluation of preoperative staging for esophageal squamous cell carcinoma. World J. Gastroenterol. 22, 6683-6689.
[20]	Mezzanotte, J.J., Hill, V., Schmidt, M.L., Shinawi, T., Tommasi, S., Krex, D., Schackert, G., Pfeifer, G.P., Latif, F., Clark, G.J., 2014. RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells. Epigenetics 9, 1496-1503.
[21]	Ocana, O.H., Corcoles, R., Fabra, A., Moreno-Bueno, G., Acloque, H., Vega, S., Barrallo-Gimeno, A., Cano, A., Nieto, M.A., 2012. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 22, 709-724.
[22]	Pastushenko, I., Blanpain, C., 2019. EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol. 29, 212-226.
[23]	Qi, L., Lu, Z., Sun, Y.H., Song, H.T., Xu, W.K., 2016. TRIM16 suppresses the progression of prostate tumors by inhibiting the Snail signaling pathway. Int. J. Mol. Med. 38, 1734-1742.
[24]	Sabouny, R., Fraunberger, E., Geoffrion, M., Ng, A.C., Baird, S.D., Screaton, R.A., Milne, R., McBride, H.M., Shutt, T.E., 2017. The Keap1-Nrf2 Stress Response Pathway Promotes Mitochondrial Hyperfusion Through Degradation of the Mitochondrial Fission Protein Drp1. Antioxid. Redox Signal. 27, 1447-1459.
[25]	Skazik, C., Heise, R., Ott, H., Czaja, K., Marquardt, Y., Merk, H.F., Baron, J.M., 2011. Active transport of contact allergens in human monocyte-derived dendritic cells is mediated by multidrug resistance related proteins. Arch. Biochem. Biophys. 508, 212-216.
[26]	Tan, H., Qi, J., Chu, G., Liu, Z., 2017. Tripartite Motif 16 Inhibits the Migration and Invasion in Ovarian Cancer Cells. Oncol. Res. 25, 551-558.
[27]	Vincent, T., Neve, E.P., Johnson, J.R., Kukalev, A., Rojo, F., Albanell, J., Pietras, K., Virtanen, I., Philipson, L., Leopold, P.L., Crystal, R.G., de Herreros, A.G., Moustakas, A., Pettersson, R.F., Fuxe, J., 2009. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat. Cell Biol. 11, 943-950.
[28]	Volodko, N., Gordon, M., Salla, M., Ghazaleh, H.A., Baksh, S., 2014. RASSF tumor suppressor gene family: biological functions and regulation. FEBS Lett. 588, 2671-2684.
[29]	Xu, G., Chen, W., Song, L., Chen, Q., Zhang, H., Liao, H., Zhao, G., Lin, F., Zhou, H., Yu, F., 2019. FERONIA phosphorylates E3 ubiquitin ligase ATL6 to modulate the stability of 14-3-3 proteins in plant C/N responses. J. Exp. Bot. Doi: 10.1093/jxb/erz378.
[30]	Xu, X., Iwasa, H., Hossain, S., Sarkar, A., Maruyama, J., Arimoto-Matsuzaki, K., Hata, Y., 2017. BCL-XL binds and antagonizes RASSF6 tumor suppressor to suppress p53 expression. Genes Cells 22, 993-1003.t
[31]	Yang, Z., Zeng, H., Xia, R., Liu, Q., Sun, K., Zheng, R., Zhang, S., Xia, C., Li, H., Liu, S., Zhang, Z., Liu, Y., Guo, G., Song, G., Zhu, Y., Wu, X., Song, B., Liao, X., Chen, Y., Wei, W., Zhuang, G., Chen, W., 2018. Annual cost of illness of stomach and esophageal cancer patients in urban and rural areas in China: A multi-center study. Chin. J. Cancer Res. 30, 439-448.
[32]	Ye H.L., Li D.D., Lin Q., Zhou Y., Zhou Q.B., Zeng B., Fu Z.Q., Gao W.C., Liu Y.M., Chen R.W., Li Z.H., Chen R.F., 2015. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival. World J. Gastroenterol. 21, 6621-6630.
[33]	Zeng, H., Chen, W., Zheng, R., Zhang, S., Ji, J.S., Zou, X., Xia, C., Sun, K., Yang, Z., Li, H., Wang, N., Han, R., Liu, S., Li, H., Mu, H., He, Y., Xu, Y., Fu, Z., Zhou, Y., Jiang, J., Yang, Y., Chen, J., Wei, K., Fan, D., Wang, J., Fu, F., Zhao, D., Song, G., Chen, J., Jiang, C., Zhou, X., Gu, X., Jin, F., Li, Q., Li, Y., Wu, T., Yan, C., Dong, J., Hua, Z., Baade, P., Bray, F., Jemal, A., Yu, X.Q., He, J., 2018. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Global Health 6, e555-e567.
[34]	Zheng, S., Houseman, E.A., Morrison, Z., Wrensch, M.R., Patoka, J.S., Ramos, C., Haas-Kogan, D.A., McBride, S., Marsit, C.J., Christensen, B.C., Nelson, H.H., Stokoe, D., Wiemels, J.L., Chang, S.M., Prados, M.D., Tihan, T., Vandenberg, S.R., Kelsey, K.T., Berger, M.S., Wiencke, J.K., 2011. DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. Neuro Oncol. 13, 280–289.